381 results on '"Bessette L"'
Search Results
2. AB0634 PREDICTORS OF CDAI TRAJECTORIES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT: A REAL-WORLD STUDY
3. AB0868 HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
4. OP0064 CHARACTERIZING PREVALENT NON-ARTICULAR PAIN AT EARLY RA DIAGNOSIS AND EVOLUTION OVER THE FIRST YEAR OF RA TREATMENT: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT STUDY
5. Profil de tolérance de l’upadacitinib chez des patients atteints de polyarthrite rhumatoïde après une durée d’exposition pouvant aller jusqu’à 6,5 ans
6. Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression
7. POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
8. POS0826 SAFETY PROFILE OF UPADACITINIB UP TO 6.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
9. AB0947 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO BIOLOGIC THERAPY
10. POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
11. POS0471 SPECIFIC SYMPTOM CLUSTERS AT DIAGNOSIS SIGNAL A POORER EARLY RA PROGNOSIS: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT
12. POS0849 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM THE SELECT-COMPARE STUDY
13. POS0057 WHICH ADVANCED TREATMENT SHOULD BE USED FOLLOWING THE FAILURE OF A FIRST-LINE ANTI-TNF IN PATIENTS WITH RHEUMATOID ARTHRITIS? 15 YEARS OF EVIDENCE FROM THE QUEBEC REGISTRY RHUMADATA™
14. POS0458 HAVING MORE TENDER THAN SWOLLEN JOINTS IS ASSOCIATED WITH WORSE FUNCTION, PAIN INTERFERENCE, SOCIAL PARTICIPATION AND OTHER HR-QOL OUTCOMES IN THE FIRST YEAR FOLLOWING RA DIAGNOSIS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT STUDY
15. POS0584-HPR PROS AND DISEASE ACTIVITY IN YEAR PRIOR TO COVID PREDICT TRAJECTORIES OF DEPRESSION IN ADULTS WITH RA IN FIRST 2 YEARS OF PANDEMIC: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT
16. Effet de l’upadacitinib, de l’adalimumab et d’un placebo sur la douleur résiduelle chez des patients atteints de polyarthrite rhumatoïde dont l’inflammation s’est atténuée après trois et six mois de traitement
17. The current economic burden of illness of osteoporosis in Canada
18. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis
19. Study of a hempcrete wall exposed to outdoor climate: effects of the coating
20. OP0308-HPR MORE THAN HALF OF RA PATIENTS WITH A LIFETIME HISTORY OF MOOD DISORDERS WERE ANXIOUS AND DEPRESSED DURING THE COVID-19 PANDEMIC: RESULTS FROM THE CANADIAN EARLY COHORT (CATCH) STUDY
21. POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS
22. AB1180 COVID-19 HAD DISPROPORTIONATE IMPACTS ON RA SYMPTOMS AND FUNCTION BY SEX AND AGE: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH)
23. AB0357 INCIDENCE AND DETERMINANTS OF INFECTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB IN REAL-WORLD PRACTICE
24. POS0643 SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL
25. POS0607 IMPROVING TREAT-TO-TARGET IMPLEMENTATION IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW OF BARRIERS, FACILITATORS, AND INTERVENTIONS
26. OP0229 OSTEOARTHRITIS OF THE KNEE, INFLAMMATION, AND THE EFFECT OF ADALIMUMAB (OKINADA): A RANDOMIZED PLACEBO-CONTROLLED TRIAL
27. POS0288 A CANADIAN RETROSPECTIVE CHART REVIEW EVALUATING CONCOMITANT METHOTREXATE DE-ESCALATION PATTERNS IN RA PATIENTS TREATED WITH BIOLOGIC OR TARGETED SYNTHETIC DMARDS
28. Development and Validation of an Intracranial Hemorrhage Risk Score in Older Adults with Atrial Fibrillation Treated with Oral Anticoagulant
29. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
30. Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort
31. Association entre une amélioration cliniquement significative des douleurs rachidiennes, les résultats rapportés par les patients et l’activité de la maladie, chez des patients ayant une spondylarthrite ankylosante : résultats d’une étude de phase 2/3
32. Effet d’upadacitinib sur la diminution des douleurs induites par le rhumatisme psoriasique actif : résultats de deux études de phase III menées chez des patients présentant une réponse inadéquate aux DMARD biologiques ou non biologiques
33. Impact de l’amélioration précoce de la douleur sur les résultats rapportés par les patients atteints de rhumatisme psoriasique : résultats d’une étude de phase III
34. Profil de tolérance intégré d’upadacitinib chez des patients atteints de polyarthrite rhumatoïde après une durée d’exposition pouvant aller jusqu’à 4,5 ans
35. The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture
36. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS)
37. IN A 2-YEAR DOUBLE-BLIND RANDOMIZED CONTROLLED MULTICENTER STUDY, CHONDROITIN SULFATE WAS SIGNIFICANTLY SUPERIOR TO CELECOXIB AT REDUCING CARTILAGE LOSS WITH SIMILAR EFFICACY AT REDUCING DISEASE SYMPTOMS IN KNEE OSTEOARTHRITIS PATIENTS: C045
38. Validity of the Health Assessment Questionnaire Predicting All‐Cause Mortality in Early Rheumatoid Arthritis: Reply to three letters to the editor
39. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review
40. Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over
41. The burden of illness of osteoporosis in Canada
42. AB0557 ACHIEVING TREATMENT TARGETS IN PSORIATIC ARTHRITIS WITH APREMILAST IN CANADIAN PRACTICE: REAL WORLD RESULTS FROM APPRAISE
43. AB0558 CLINICAL EFFECTIVENESS AND SAFETY OF ADALIMUMAB VERSUS NON-BIOLOGIC THERAPY IN PSORIATIC ARTHRITIS PATIENTS OVER 24 MONTHS – RESULTS OF THE COMPLETE-PsA CANADIAN OBSERVATIONAL STUDY
44. POS1047 IMPACT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH INADEQUATE RESPONSE TO NON-BIOLOGIC OR BIOLOGIC DMARDs
45. POS1459-HPR IDENTIFYING MEANINGFUL CHANGE IN THE RA FLARE QUESTIONNAIRE SCORES IN RHEUMATOID ARTHRITIS
46. POS0220 INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
47. AB0555 IMPACT OF ADALIMUMAB VERSUS NON-BIOLOGIC THERAPY ON CLINICAL AND PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS OVER 24 MONTHS – RESULTS OF THE COMPLETE-PsA CANADIAN OBSERVATIONAL STUDY
48. OP0262-HPR THE NEURO-QOL UPPER EXTREMITY FUNCTION SCALE: NEW OPPORTUNITIES TO MORE RELIABLY AND PRECISELY MEASURE SELF-REPORTED HAND FUNCTION AND SELF-CARE ACTIVITIES IN PEOPLE WITH RA
49. POS0531 FACTORS ASSOCIATED WITH BASELINE HYPERTENSION IN EARLY RHEUMATOID ARTHRITIS: DATA FROM A REAL-WORLD LARGE INCIDENT COHORT
50. POS0232 CLINICAL EFFECTIVENESS OF ADALIMUMAB VERSUS NON-BIOLOGIC THERAPY IN THE MANAGEMENT OF EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS PATIENTS OVER 24 MONTHS – RESULTS OF THE COMPLETE-AS CANADIAN OBSERVATIONAL STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.